Source:http://linkedlifedata.com/resource/pubmed/id/14601997
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
23
|
pubmed:dateCreated |
2003-11-6
|
pubmed:abstractText |
[reaction: see text] A general demonstration of orthogonal selectivity of the Liebeskind-Srogl cross-coupling protocol compared to the Suzuki-Miyaura and Stille variants is reported.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:status |
PubMed-not-MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1523-7060
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
13
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
4349-52
|
pubmed:year |
2003
|
pubmed:articleTitle |
Switchable catalysis: modular synthesis of functionalized Pyrimidinones via selective sulfide and halide cross-coupling chemistry.
|
pubmed:affiliation |
Pfizer Global Research and Development, St. Louis Laboratories, 800 North Lindbergh, St. Louis, Missouri, USA.
|
pubmed:publicationType |
Journal Article
|